Femasys announced the appointment of Richard Spector to chief commercial officer, CCO, effective February 2024. Spector has 25 years of experience spanning a continuum of commercial stages at both public and private medical device and biopharmaceutical companies. Most recently, Spector was chief commercial officer at Qlibrium.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on FEMY:
- Femasys Inc. Advances Commercial Readiness with Appointment of Richard Spector to New Position of Chief Commercial Officer
- Femasys begins enrollment for FemBloc trial
- Femasys Inc. Begins FemBloc Pivotal Trial Enrollment at UC Davis Medical Center, a Hub for Innovation and Groundbreaking Research in Health Care for Women
- Femasys Inc. Begins FemBloc Pivotal Trial Enrollment at University of Utah, an Internationally Recognized Center in Obstetrics and Gynecology
- Femasys begins FemBloc trial enrollment at University of Utah
